Zimmer Biomet Raises 2026 EPS Target to $8.59 as Hips and Tech Outsell the Street's Fears

Why Zimmer's guide raise matters

Zimmer Biomet lifted its 2026 adjusted EPS target to $8.47–$8.59 after reporting $2.177 billion in Q2 net sales, up 4.8% reported, and $2.07 in adjusted diluted EPS. The quarter itself was not a dramatic earnings leap, but the guidance increase suggests management sees real traction going into the second half.

For investors, the key point is not just the higher target. It is that the company moved both revenue and earnings expectations after a quarter that showed improvement in core growth drivers, even if margin expansion has not yet fully appeared.

Hips and technology are leading the recovery

The improvement is showing up in the right places. Zimmer's best core franchise, hips, posted 5.1% constant-currency growth, including 5.9% U.S. growth, helped by adoption of the Z1 stem and HAMMR impaction device. That suggests product acceptance is helping Zimmer win more business in the operating room, rather than relying on a broad recovery in case volume alone.

Technology and data was an even faster mover. The segment grew 21.5%, with U.S. technology growth exceeding 50% and support from record capital sales. That matters because capital equipment can help make future usage more durable, not just more cyclical.

There was also useful breadth from the broader commercial effort. Zimmer's SET portfolio accelerated to 3.4% organic growth, led by mid-teens gains at Paragon 28. So the turnaround is not hanging only on hips.

What the rest of the guide raise says about execution

The U.S. sales force transformation is now in stage two, with management describing minimal disruption. Zimmer also added technology reps, while saying demand for its iodine-coated hip in Japan has exceeded expectations on premium pricing and competitive conversions. Taken together, those details make the guide raise look more credible than a simple market rebound.

The caution remains real too. Knees were flat, pressured by international weakness, so the recovery is not yet broad enough to call a complete turnaround. But the improving pieces are strong enough to support a more constructive near-term outlook.

What investors should watch from here

The practical test now is whether Zimmer can defend its new targets. Management raised its full-year organic revenue growth guidance of 2.25%–3.25%, and staying around the midpoint or above would matter more than another recap of Q2.

The buyback increase to $1 billion also adds context. It does not prove the turnaround is complete, but it does suggest management sees the cash engine as steadier.

The clearest signals to watch are: - whether the U.S. sales force transformation continues with minimal disruption - whether international weakness keeps fading - whether China headwinds ease as management expects - whether technology capital sales help build a more durable equipment-and-consumables cycle - and whether more of the sales improvement shows up in profit

The easy repricing is likely behind us. A stronger case for a richer multiple probably needs broader product-line participation and clearer margin conversion.